July 21, 2015

New Evidence That Ablation May Be Best Option for AFib in Heart Failure

Procedure yields better outcomes than amiodarone

Catheter ablation

The recently presented AATAC-AF in Heart Failure study shows that performing catheter ablation for persistent atrial fibrillation in patients with heart failure appears to be worth the risks, according to Cleveland Clinic electrophysiologist Walid Saliba, MD.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Keeping this group of patients out of atrial fibrillation is definitely an unmet need today,” says Dr. Saliba, who was not involved in the study. “They have higher hospitalization rates and higher recurrence rates of atrial fibrillation because it tends to coexist with heart failure.”

The study at a glance

The study, which was presented at the American College of Cardiology Scientific Session earlier this year, was a multicenter comparison of catheter ablation with the antiarrhythmia medication amiodarone in 203 patients with NYHA class II to III heart failure plus atrial fibrillation. All patients had a left ventricular ejection fraction (LVEF) less than 40 percent and a dual-chamber implantable cardioverter defibrillator or cardiac resynchronization therapy device. Patients were randomized to catheter ablation or amiodarone in a parallel-group, open-label fashion.

Dr. Saliba notes that this study differed from prior comparisons of amiodarone with ablation for atrial fibrillation because it looked exclusively at patients who also had heart failure.

At mean follow-up of 26 months, 70 percent of patients in the catheter ablation group showed freedom from atrial fibrillation compared with 34 percent randomized to amiodarone (P < .001). The ablation group also showed statistically significant advantages in all-cause mortality and hospitalization rates.

Advertisement

The study found that heart function improved by significantly greater degrees among recurrence-free patients compared with patients who experienced atrial fibrillation recurrence, in terms of LVEF, six-minute walk distance and Minnesota functioning score (P < .001 for all).

Comparing risks with ablation vs. meds

Dr. Saliba says that while ablation procedures have some risks, this study helps show that many of the risks are worth it. He notes that amiodarone also poses risks, and patients taking it for a long time need regular monitoring of the thyroid, liver, lungs, eyes, skin and central nervous system.

“Amiodarone is a strong medication,” he says, “and we do not like to give it to young patients since they would face years of possible side effects. We have thought it was best used for a short time with a specific goal, such as until the patient can undergo ablation. This study shows that this is the correct approach for most patients.”

He notes, however, that ablation does not “cure” atrial fibrillation, especially in patients with concomitant heart failure; instead, it tends to maximize the chance of staying in normal rhythm. Patients who still have symptoms, such as dyspnea, may need to try antiarrhythmic drug therapy as well.

Advertisement

‘A step in the right direction’

Dr. Saliba points out that AATAC-AF in Heart Failure was a small study and that more research on the best ways to treat atrial fibrillation in heart failure is needed, but he calls it a step in the right direction.

“Overall mortality in this study was 8 percent in the ablation group vs. 18 percent in the amiodarone group,” he says. “This is a positive finding that helps reaffirm results from other studies showing that ablation offers the greatest chance of success for heart failure patients.”

He adds that keeping patients in normal rhythm without medication means that “we are potentially changing the natural history of the disease.”

Related Articles

21-HVI-2541213_chest-pain_650x450
December 14, 2021
New Guideline Helps Evaluate Risk in Patients With Chest Pain

Further acute testing not needed if ECG and high-sensitivity troponin are negative

20-HVI-1987645-scott-cameron-md-phd_650x450
November 6, 2020
New Head of Vascular Medicine Looks to Enhance Collaborative Caregiving

Scott Cameron, MD, PhD, also brings wide-ranging research interests to bear

20-HVI-1961368_Matthew-Thompson_650x450
September 30, 2020
Dr. Matthew Thompson Brings a Distinctly International Perspective to Endovascular Interventions

Pioneering U.K. vascular surgeon joins Cleveland Clinic

20-HVI-1961369-acute-stroke-in-brain_650x450
September 24, 2020
Stroke Risk in Cardiac Surgery: New Guidance for Averting a Dreaded Complication

AHA statement is first comprehensive document on perioperative stroke reduction

20-HVI-1896881 vascular-surgery-650&#215;450
July 17, 2020
Cleveland Clinic Earns 3 Stars in Vascular Quality Initiative Registry Participation Program

Recognition reflects prioritization of long-term patient outcomes

20-HVI-1898975 Singh_Guidelines on CV imaging in athletes_CQD_650x450_993744768
June 15, 2020
First Formal Guidance Issued on Multimodality Cardiac Imaging in Young Athletes

Recommendations help distinguish exercise-induced remodeling from pathology

20-HVI-1894191-Primary-prevention-of-CVD-in-women
May 29, 2020
Guideline Update on Primary Cardiovascular Prevention in Women Takes on Conventional and Sex-Specific Risks

JACC review highlights factors unique to women, ways to tailor management

20-HVI-1892867-ablation-roundup-650&#215;450
May 12, 2020
Trio of Studies at Virtual HRS Meeting Showcase Catheter Ablation Advances

Pushing the envelope in ablation of atrial fibrillation, ventricular tachycardia

Ad